STAT6 Inhibition of M2 Macrophages in a Colon Cancer Model

A research document detailing a preclinical study on targeting M2 tumor-associated macrophages in colorectal cancer. The study evaluates a peptide drug conjugate, TAMpep-IP, designed to inhibit STAT6 signaling and its effects on tumor growth and immune cell populations in a CT26 murine model. The document was authored by Geumseong Yeun and last updated on June 3, 2026.

Use Cases

• Analyze the relationship between STAT6 inhibition and M2 macrophage marker expression based on described measurements of CD206, Arg-1, TGF-β, and IL-13.
• Study the impact of macrophage phenotype on cytotoxic T-cell activity based on reported changes in Granzyme B+ CD8+ T cells and exhausted T-cell markers.
• Investigate therapeutic strategies for modulating the immunosuppressive tumor microenvironment based on the described preclinical model and treatment outcomes.

Strengths

• The study includes in vivo validation in a CT26 murine colon cancer model, as described.
• The document provides specific molecular targets and outcomes, such as changes in STAT6 phosphorylation and cytokine levels like TNF-α, IL-1β, and IL-12.

Limitations

• The dataset is a 998.6 KB DOCX file, which is a small document rather than a structured data repository.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for quantitative analysis.

Provenance

Source

figshare

Collection Method

Preclinical research involving in vitro assays on THP-1-derived macrophages and in vivo experiments in a mouse model, as described.

Freshness

Last updated 2026-06-03 06:08:13; freshness should be verified.